Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first-line sunitinib: A medical chart review across ten centers in five European countries

  1. Porta, C.
  2. Levy, A.
  3. Hawkins, R.
  4. Castellano, D.
  5. Bellmunt, J.
  6. Nathan, P.
  7. Mcdermott, R.
  8. Wagstaff, J.
  9. Donnellan, P.
  10. Mccaffrey, J.
  11. Vekeman, F.
  12. Neary, M.P.
  13. Diaz, J.
  14. Mehmud, F.
  15. Duh, M.S.
Aldizkaria:
Cancer Medicine

ISSN: 2045-7634

Argitalpen urtea: 2014

Alea: 3

Zenbakia: 6

Orrialdeak: 1517-1526

Mota: Artikulua

DOI: 10.1002/CAM4.302 GOOGLE SCHOLAR lock_openSarbide irekia editor
Datuen iturria: Scopus